Second-Line Antiretroviral Treatment Successfully Resuppresses Drug-Resistant HIV-1 After First-Line Failure: Prospective Cohort in Sub-Saharan Africa

被引：57

作者：

Sigaloff, Kim C. E. ^{[1
]}

Hamers, Raph L. ^{[1
]}

Wallis, Carole L. ^{[2
]}

Kityo, Cissy ^{[3
]}

Siwale, Margaret ^{[4
]}

Ive, Prudence ^{[2
]}

Botes, Mariette E. ^{[5
]}

Mandaliya, Kishor ^{[6
]}

Wellington, Maureen ^{[7
]}

Osibogun, Akin ^{[8
]}

Stevens, Wendy S. ^{[2
]}

van Vugt, Michele ^{[9
]}

de Wit, Tobias F. Rinke ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Global Hlth & Dev, PharmAccess Fdn,Dept Global Hlth, NL-1100 DE Amsterdam, Netherlands

[2] Univ Witwatersrand, Dept Mol Med & Haematol, Johannesburg, South Africa

[3] Joint Clin Res Ctr, Kampala, Uganda

[4] Lusaka Trust Hosp, Lusaka, Zambia

[5] Muelmed Hosp, Pretoria, South Africa

[6] Coast Prov Gen Hosp, Int Ctr Reprod Hlth, Mombasa, Kenya

[7] Newlands Clin, Harare, Zimbabwe

[8] Univ Lagos, Teaching Hosp, Lagos, Nigeria

[9] Univ Amsterdam, Acad Med Ctr, Div Infect Dis, Dept Internal Med, NL-1100 DE Amsterdam, Netherlands

来源：

JOURNAL OF INFECTIOUS DISEASES | 2012年 / 205卷 / 11期

关键词：

THERAPY; MORTALITY; RITONAVIR;

D O I：

10.1093/infdis/jis261

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associated with treatment failure were assessed using logistic regression. Of 243 participants, 53% were predicted to receive partially active second-line regimens due to drug resistance. The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure.

引用

页码：1739 / 1744

页数：6

共 15 条

[1]

[Anonymous], ANT THER HIV INF AD

[2]

[Anonymous], INT J EPIDEMIOL

[3]

Bartlett JA, 2011, 18 C RETR OPP INF CR

[4] HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review [J].

Bierman, Wouter F. W. ;

van Agtmael, Michiel A. ;

Nijhuis, Monique ;

Danner, Sven A. ;

Boucher, Charles A. B. .

AIDS, 2009, 23 (03) :279-291

[5]

Bunupuradah T, 2011, 18 C RETR OPP INF CR

[6] High Rates of Survival, Immune Reconstitution, and Virologic Suppression on Second-Line Antiretroviral Therapy in South Africa [J].

Fox, Matthew P. ;

Ive, Prudence ;

Long, Lawrence ;

Maskew, Mhairi ;

Sanne, Ian .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (04) :500-506

[7] Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline* [J].

Hosseinipour, M. C. ;

Kumwenda, J. J. ;

Weigel, R. ;

Brown, L. B. ;

Mzinganjira, D. ;

Mhango, B. ;

Eron, J. J. ;

Phiri, S. ;

van Oosterhout, J. J. .

HIV MEDICINE, 2010, 11 (08) :510-518

[8] The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy [J].

Hosseinipour, Mina C. ;

van Oosterhout, Joep J. G. ;

Weigel, Ralf ;

Phiri, Sam ;

Kamwendo, Debbie ;

Parkin, Neil ;

Fiscus, Susan A. ;

Nelson, Julie A. E. ;

Eron, Joseph J. ;

Kumwenda, Johnstone .

AIDS, 2009, 23 (09) :1127-1134

[9]

Johnson Victoria A, 2010, Top HIV Med, V18, P156

[10] Web resources for HIV type 1 genotypic-resistance test interpretation [J].

Liu, TF ;

Shafer, RW .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (11) :1608-1618

← 1 2 →